Skip to content
Tech Insights Blog

Giving Pluripotent Cells in Utero to Babies with Neural Tube Defect Enhances Quality of Life, Research Shows

A pioneering medical trial has revealed that delivering regenerative cells to unborn babies affected by spina bifida while undergoing fetal surgery could constitute a "important advancement" in treating birth defects.

Study Parameters and Security

The US-based trial focused on six developing infants with myelomeningocele. Surgeons applied mother's placental stem cells on the exposed area of the baby's spinal cord during the repair procedure.

Importantly, the regenerative treatment was found to be safe. Doctors verified that the treatment did not lead to neoplasms, hinder surgical recovery, or impede the resolution of associated brain abnormalities.

Promising Outcomes

Magnetic resonance imaging performed on the newborns indicated a complete reversal of Chiari malformation in all six infants. This brain structure normalization is closely linked to improved motor skills and quality of life.

"In the event it allows a greater number of infants able to walk who previously could not, it may emerge as their standard of care," commented the principal investigator. "The results are extremely promising and pave the way for numerous possible new treatments."

Future Implications and Hope

Experts not involved in the trial have suggested that subsequent studies of these noted improvements could announce a "fresh chapter" in fetal surgery. The prospect of enhancing neurological damage seen in utero is viewed as a transformative goal.

Particularly welcome would be improvements in bladder and bowel function, which are common challenges for those diagnosed with this disorder.

Future Directions

Despite this being a first-in-human effort was small in scale, its safety demonstration and positive signals create a solid basis for broader investigative efforts. The addition of cellular treatment with proven prenatal surgical methods presents significant potential for transforming outcomes for babies yet to be born with myelomeningocele.

By

Amy Nichols

A software engineer and tech enthusiast with over 10 years of experience in AI development and digital transformation projects.

Tech Insights Blog

Type to search articles.